LINCOLN, Neb.--(BUSINESS WIRE)--Celerion is pleased to announce the appointment of Clayton Dehn as Executive Director, Metabolic Diseases. Mr. Dehn will lead the expansion of Celerion's current capabilities that support early Proof-of-Concept in the development of diabetes, obesity, metabolic and cardio-metabolic interventions.
The appointment of Mr. Dehn reinforces Celerion's commitment to accelerating drug development through Applied Translational Medicine. Clients working in the metabolic area will have access to an arsenal of complex, highly sensitive pharmacodynamic tests capable of detecting early signals of efficacy. These capabilities combined with Celerion's expertise in conducting complex early clinical PK/PD studies in healthy participants and patients, provide an effective platform to generate data and information. This improves the quality of decision-making in the drug development process, enabling both time and cost savings.
Within the metabolic disease area, the glucose clamp is the gold-standard measure of insulin sensitivity, beta cell sensitivity, and characterization of the time-action profiles of insulin products. It is an intricate yet powerful, highly sensitive, well established technique that can enhance the value of early clinical research efforts in the development of agents for the treatment of both Type 1 and Type 2 diabetes. Mr. Dehn has experience in conducting thousands of glucose clamps and brings his substantial expertise in a variety of metabolic research tools that include:
- Oral Glucose Tolerance Tests (OGTT)
- Meal Tolerance Tests (MTT)
- Intravenous Glucose Tolerance Tests (IVGTT)
- Maximum Stimulation Tests
- Graded Glucose Infusions
- Stable Isotope Dilution Methods
- Glucose Clamps
- Flow Mediated Dilation (FMD)
"We are very pleased to have Clayton join the Global Clinical Research team at Celerion," said Phil Bach, Vice President, Global Clinical Research at Celerion. "His comprehensive knowledge of specialized metabolic testing methods and hands-on operational experience will be a great asset to our organization and clients' drug development programs."
Mr. Dehn comes to Celerion with 15 years of experience in drug development. He has led highly successful metabolic programs at two leading Contract Research Organizations (CROs), and also served as Director of Clinical Research and Development at a start-up biotech company developing investigational devices, techniques and compounds for use in assisted reproduction. Mr. Dehn earned a Master of Science in Physiology and Bachelors of Science in Animal Science from Texas Tech University.
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, cardiac safety services (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion's service offerings. For more information please visit www.celerion.com.
Farzana Azam, +1 647-261-3628
Executive Director, Global Marketing